Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia By webmaster / June 16, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study By webmaster / June 16, 2025
Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs By webmaster / April 25, 2025
NX-5948 and NX-2127 Potently Degrade a Broad Array of Clinically-Relevant BTK Mutants That Display Resistance to Inhibitors and Other BTK Degraders By webmaster / March 25, 2025
NX-5948 Promotes Selective, Sub-Nanomolar Degradation Of Inhibitor-Resistant BTK Mutants By aterrado@waterhousebrands.com / January 7, 2025
First Disclosure Of NX-5948, An Oral Targeted Degrader Of Bruton’s Tyrosine Kinase (BTK) For The Treatment Of B-Cell Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948: BTK Degrader with Activity in Lymphoid Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases By aterrado@waterhousebrands.com / January 7, 2025
Efficacy And Safety Of The Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From An Ongoing Phase 1A/B Study By aterrado@waterhousebrands.com / January 7, 2025
